Do you want to read an article? Please log in or register.
Insulin Resistance in Type 1 Diabetes Managed with Metformin (INTIMET): study protocol of a double-blind placebo-controlled, randomised trial
Type 1 Diabetes
Related content
Diabetes - GeneralType 1 DiabetesGlycemic Control
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
Lancet Diabetes Endocrinol.
Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group
doi: 10.1016/
Type 1 DiabetesGlycemic Control
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
★ 0
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Johansen NJ, Dejgaard TF, Lund A, Schlüntz C, Frandsen CS, Forman JL, Wewer Albrechtsen NJ, Holst JJ, Pedersen-Bjergaard U, Madsbad S, Vilsbøll T, Andersen HU, Knop FK
doi: 10.1016/S2213-8587(20)30030-9.
Diabetes - GeneralType 2 Diabetes
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial
Lancet Diabetes Endocrinol.
Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016
doi: 10.1016/
Type 1 DiabetesObesity and Bariatric Surgery
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial - a randomized, double-blinded, placebo-controlled trial
Diabetes Obes Metab.
Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU, Nørgaard K
doi: 10.1111/dom.13911.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol.
Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z
doi: 10.1016/S2213-8587
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Lancet Diabetes Endocrinol.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC
doi: 10.1016/
Diabetes - GeneralType 2 DiabetesObesity and Bariatric Surgery
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Lancet.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, Ortiz RV, Wilding JP, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group
doi: 10.1016/
COMMENTED
Type 2 DiabetesGlycemic Control
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, Fantus IG, Hutton E, Armson AB, Lipscombe LL, Simmons D, Barrett JFR, Karanicolas PJ, Tobin S, McIntyre HD, Tian SY, Tomlinson G, Murphy KE, MiTy Collaborative Group.
doi: 10.1016/S2213-8587(20)30310-7
Type 2 Diabetes
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Diabetes Care.
Latva-Rasku A, Honka MJ, Kullberg J, Mononen N, Lehtimäki T, Saltevo J, Kirjavainen AK, Saunavaara V, Iozzo P, Johansson L, Oscarsson J, Hannukainen JC, Nuutila P
doi: 10.2337/dc18-1569.